|
Dementia
|
0.010 |
Biomarker
|
disease |
BEFREE |
To observe the effect of early intervention using extract of Huannao Yicong Decoction (, HYD) on the pathological picture of hippocampus, neurocyte apoptosis, and associated regulatory genes in β-amyloid precursor protein (APP) transgenic mice model of dementia.
|
21660677 |
2011 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Supporting the relevance of EDD1 and GRHL2 as therapeutic candidates to engage apoptosis in cancer cells, silencing the expression of either gene sensitizes 8q22-amplified breast cancer cell lines to death receptor induced apoptosis.
|
21949371 |
2011 |
|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Supporting the relevance of EDD1 and GRHL2 as therapeutic candidates to engage apoptosis in cancer cells, silencing the expression of either gene sensitizes 8q22-amplified breast cancer cell lines to death receptor induced apoptosis.
|
21949371 |
2011 |
|
Malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
By using a series of silencing and overexpression studies, we show that EDD1 and GRHL2 suppress death-receptor expression, and that EDD1 expression is elevated in breast, pancreas, and lung cancer cell lines resistant to death receptor-mediated apoptosis.
|
21949371 |
2011 |
|
Carcinoma of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
By using a series of silencing and overexpression studies, we show that EDD1 and GRHL2 suppress death-receptor expression, and that EDD1 expression is elevated in breast, pancreas, and lung cancer cell lines resistant to death receptor-mediated apoptosis.
|
21949371 |
2011 |
|
Primary malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
By using a series of silencing and overexpression studies, we show that EDD1 and GRHL2 suppress death-receptor expression, and that EDD1 expression is elevated in breast, pancreas, and lung cancer cell lines resistant to death receptor-mediated apoptosis.
|
21949371 |
2011 |
|
Impaired cognition
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies multiple novel loci associated with disease progression in subjects with mild cognitive impairment.
|
22833209 |
2011 |
|
Alzheimer's Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
These top variants (rs7840202 at chr8 in UBR5: P=4.27 × 10(-14); rs11637611 with a cluster of SNPs at chr15q23 close to the Tay-Sachs disease locus: P=1.07 × 10(-15); and rs12752888 at chr1: P=3.08 × 10(-11)) were also associated with a significant decline in cognition as well as the conversion of subjects with MCI to a diagnosis of AD.
|
22833209 |
2011 |
|
Tay-Sachs Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
These top variants (rs7840202 at chr8 in UBR5: P=4.27 × 10(-14); rs11637611 with a cluster of SNPs at chr15q23 close to the Tay-Sachs disease locus: P=1.07 × 10(-15); and rs12752888 at chr1: P=3.08 × 10(-11)) were also associated with a significant decline in cognition as well as the conversion of subjects with MCI to a diagnosis of AD.
|
22833209 |
2011 |
|
Mild cognitive disorder
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
These top variants (rs7840202 at chr8 in UBR5: P=4.27 × 10(-14); rs11637611 with a cluster of SNPs at chr15q23 close to the Tay-Sachs disease locus: P=1.07 × 10(-15); and rs12752888 at chr1: P=3.08 × 10(-11)) were also associated with a significant decline in cognition as well as the conversion of subjects with MCI to a diagnosis of AD.
|
22833209 |
2011 |
|
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma.
|
23407552 |
2013 |
|
Mantle cell lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The recurrence and clustering of deleterious mutations implicate UBR5 mutations as a critical pathogenic event in a subgroup of MCL.
|
23407552 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, the B55α-EDD-p53 pathway is essential for cancer cell survival and tumor growth under low glutamine conditions in vitro and in vivo.
|
23499005 |
2013 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Importantly, the B55α-EDD-p53 pathway is essential for cancer cell survival and tumor growth under low glutamine conditions in vitro and in vivo.
|
23499005 |
2013 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Importantly, the B55α-EDD-p53 pathway is essential for cancer cell survival and tumor growth under low glutamine conditions in vitro and in vivo.
|
23499005 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Constitutive expression of UBR5-ZNF423 in NIH3T3 fibroblasts significantly enhanced its anchorage-independent growth in soft agar and induced tumour formation in a nude mouse model.
|
23878065 |
2013 |
|
Nasopharyngeal carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Notably, the growth of NPC cells with UBR5-ZNF423 rearrangement is dependent on expression of this fusion protein.
|
23878065 |
2013 |
|
Gestational Diabetes
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
The distribution of the variants like II, ID, and DD genotypes of ACE gene showed differences between normal GDM versus non-GDM subjects, and the frequency of the ID+ DD Vs II genotype was significant (p=0.0002) in the GDM group.
|
24189507 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo, mouse intraperitoneal ES-2 and A2780ip2 xenograft experiments showed that mice treated with EDD siRNA by nanoliposomal delivery [1,2-dioleoyl-sn-glycero-3-phophatidylcholine (DOPC)] and cisplatin had significantly less tumor burden than those treated with control siRNA/DOPC alone (ES-2, 77.9% reduction, P = 0.004; A2780ip2, 75.9% reduction, P = 0.042) or control siRNA/DOPC with cisplatin in ES-2 (64.4% reduction, P = 0.035), with a trend in A2780ip2 (60.3% reduction, P = 0.168).
|
24379240 |
2014 |
|
Malignant neoplasm of ovary
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The E3 ubiquitin ligase EDD is overexpressed in recurrent, platinum-resistant ovarian cancers, suggesting a role in tumor survival and/or platinum resistance.
|
24379240 |
2014 |
|
Carcinoma, Ovarian Epithelial
|
0.030 |
Biomarker
|
disease |
BEFREE |
EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.
|
24379240 |
2014 |
|
Epithelial ovarian cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.
|
24379240 |
2014 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Utilizing a high throughput RNAi screening approach we identified UBR5, a protein commonly amplified in breast cancer, as a novel regulator of ERα protein levels and transcriptional activity.
|
24441042 |
2015 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Utilizing a high throughput RNAi screening approach we identified UBR5, a protein commonly amplified in breast cancer, as a novel regulator of ERα protein levels and transcriptional activity.
|
24441042 |
2015 |
|
Alzheimer's Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Rats in HYDL, HYDM and HYDH were injected with Aβ<sub>1-42</sub> at the CA1 region of hippocampus to form AD model and were fed the HYD extract at different dose of 3.78, 7.56 and 18.90 g crude drug/kg.
|
27022730 |
2017 |